Colchicine combined with antiplatelet therapy offers a potential strategy to tackle atherothrombosis by targeting inflammatory pathways without increasing bleeding risk.
Does combining colchicine and antiplatelet therapy reduce atherothrombotic events in patients with coronary artery disease?
Colchicine combined with antiplatelet therapy represents a potential dual-pathway strategy targeting inflammation and platelets to reduce residual atherothrombotic risk without increasing bleeding.
Atherothrombosis, the primary driver of acute cardiovascular (CV) events, is characterized by the activation of three key pathophysiological pathways: platelets, coagulation, and inflammation. Dual antiplatelet therapy (DAPT) is the current standard of care for patients with acute coronary syndrome, providing significant reductions in cardiovascular (CV) events, albeit with an associated increased risk of bleeding. However, the high residual risk of recurrent events among these patients highlights the need for alternative strategies to treat and prevent atherothrombosis. To this extent, several approaches aimed at targeting atherothrombosis have been proposed. Among these, a strategy of dual-pathway inhibition simultaneously targeting platelets, using single or DAPT, and coagulation, using a low-dose anticoagulant such as rivaroxaban 2.5 mg twice daily, has shown to reduce CV events but at the expense of increased bleeding. Targeting inflammatory pathways has the potential to be a highly effective strategy to tackle atherothrombosis without increasing bleeding risk. Several anti-inflammatory agents have been tested in patients with coronary artery disease, but to date only colchicine is approved for secondary prevention on top of standard care, including antiplatelet therapy. However, many aspects of colchicine's mechanism of action, including its antiplatelet effects and how it synergizes with antiplatelet therapy, remain unclear. In this review, we summarize the available clinical and pre-clinical evidence on the antiplatelet effects of colchicine and its synergistic interactions with antiplatelet therapy, highlighting their potential role in addressing atherothrombosis.
Giordano et al. (Tue,) conducted a review in Atherothrombosis. Colchicine and antiplatelet therapy was evaluated. Colchicine combined with antiplatelet therapy offers a potential strategy to tackle atherothrombosis by targeting inflammatory pathways without increasing bleeding risk.